论文部分内容阅读
自1967年Segal和Croxatto提示Silastic可作为一种缓释甾体避孕药的载体以来,已经应用此法试验了一些甾体避孕药物。其中19-去甲孕激素,左旋18甲基炔诺酮都已证明Silastic可作为一种优良的载体,缓释这些药物达到长期避孕的目的。 ST-1435是一种既无雄性激素又无雌性激素性质的新的19-去甲基孕酮药物。这种避孕药的特点是口服无效,皮下给药可呈现良好的避孕活性。对脂蛋白无副作用。是一种理论上理想的哺乳期甾体避孕药。为了调查用药者对此法的接受性,作者对应用三种不同长度的ST-1435皮下避孕胶囊出现的副反应,包括出血、肝功能、垂体及卵巢功能的影响
Since 1967 Segal and Croxatto have suggested that Silastic may be used as a carrier for sustained release steroid contraceptives, some steroidal contraceptives have been tested using this method. Among them, 19-norprogestin and 18-norgestrel have all proved that Silastic can be used as an excellent carrier for sustained release of these drugs for the purpose of long-term contraception. ST-1435 is a new 19-nor progesterone drug that is neither androgen nor estrogen. This contraceptive is characterized by oral ineffective, subcutaneous administration can show good contraceptive activity. No side effects on lipoprotein. Is a theoretical ideal lactation steroid contraceptives. In order to investigate drug users’ acceptance of this method, the authors investigated the side effects of bleeding, liver function, pituitary and ovarian function in three subcutaneous contraceptive capsules of ST-1435 of varying lengths